Kinfo
Alps Group Inc. logo

Alps Group Inc.

ALPSNASDAQ·US · USD
$0.48
-0.03 (-5.01%)
Prices as of July 14, 2026 · live

Price

Key statistics

Valuation
Market cap83.35M USD
Enterprise value83.99M USD
Trailing P/E0.21
Forward P/E0.00
PEG ratio0.00
Price / sales24.73
Price / book-599.36
Profitability
Gross margin5.47%
Operating margin-73.59%
Profit margin38.60%
Return on assets-35.24%
Return on equity225.25%
Income (TTM)
Revenue3.37M USD
Gross profit1.30M USD
EBITDA127.81M USD
Net income-2.51M USD
Diluted EPS-$0.02
Rev. growth (YoY)-519.28%
Balance sheet
Total cash1.00 USD
Total debt0.00 USD
Debt / equity-0.00
Current ratio0.00
Book value / share-$0.00
Cash flow (TTM)
Operating cash flow-1.43M USD
Levered free cash flow-2.51M USD
Shares & price
Shares outstanding166.40M
Float0.00
Held by institutions0.00%
Beta0.00
50-day MA$0.73
200-day MA$0.92
52-week high$2.90
52-week low$0.48
Dividends
Forward rate
$0.38
Yield
80.67%
Payout ratio
0.00%
Frequency
Monthly
Recent payments
  • 2023-02-13$0.03
About Alps Group Inc.

Alps Group Inc. is a biotechnology and life sciences company headquartered in Kuala Lumpur, Malaysia. It operates as a fully integrated platform that encompasses biotechnology research, medical services, and wellness solutions, with a specialization in predictive, precision, and preventive health management. Through its subsidiaries, the company provides research and development for advanced therapies, including access to DNA and mRNA sequencing, cellular therapy, and anti-aging products and services. Alps Group Inc. focuses on delivering innovative wellness solutions and medical services tailored to clientele seeking cutting-edge health interventions. Its operations span the biotechnology sector, contributing to advancements in personalized medicine and life sciences applications across regional markets.

Headquarters
United States

Frequently asked questions about Alps Group Inc.